Evolus Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

David Moatazedi

Chief executive officer

US$11.2m

Total compensation

CEO salary percentage	6.1%
CEO tenure	6.5yrs
CEO ownership	n/a
Management average tenure	3yrs
Board average tenure	6.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Moatazedi's remuneration changed compared to Evolus's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$55m
Jun 30 2024	n/a	n/a	-US$53m
Mar 31 2024	n/a	n/a	-US$60m
Dec 31 2023	US$11m	US$688k	-US$62m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$66m
Mar 31 2023	n/a	n/a	-US$72m
Dec 31 2022	US$4m	US$597k	-US$74m
Sep 30 2022	n/a	n/a	-US$79m
Jun 30 2022	n/a	n/a	-US$79m
Mar 31 2022	n/a	n/a	-US$71m
Dec 31 2021	US$4m	US$572k	-US$47m
Sep 30 2021	n/a	n/a	-US$139m
Jun 30 2021	n/a	n/a	-US$131m
Mar 31 2021	n/a	n/a	-US$137m
Dec 31 2020	US$3m	US$527k	-US$163m
Sep 30 2020	n/a	n/a	-US$67m
Jun 30 2020	n/a	n/a	-US$82m
Mar 31 2020	n/a	n/a	-US$99m
Dec 31 2019	US$2m	US$550k	-US$90m
Sep 30 2019	n/a	n/a	-US$88m
Jun 30 2019	n/a	n/a	-US$73m
Mar 31 2019	n/a	n/a	-US$52m
Dec 31 2018	US$6m	US$362k	-US$47m

Compensation vs Market: David's total compensation ($USD11.24M) is above average for companies of similar size in the German market ($USD1.44M).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Moatazedi (46 yo)

6.5yrs

Tenure

US$11,240,447

Compensation

Mr. David Moatazedi is Independent Director at Biomerica Inc. from December 07, 2022. He has been the President, Chief Executive Officer and Director of Evolus, Inc. since joining it on May 6, 2018. Mr. Mo...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Moatazedi	President	6.5yrs	US$11.24m	no data
Sandra Beaver	Chief Financial Officer	2.2yrs	US$2.46m	0.052% € 396.3k
Rui Avelar	Chief Medical Officer and Head of Research & Development	10.8yrs	US$2.93m	0.31% € 2.4m
Nareg Sagherian	Head of Global Investor Relations & Corporate Communications	less than a year	no data	no data
Jeffrey Plumer	General Counsel	no data	no data	no data
Kurt Knab	Vice President of Sales	6.1yrs	no data	no data
Tomoko Yamagishi-Dressler	Chief Marketing Officer	1.3yrs	no data	0.016% € 123.4k
Jessica Novak	Senior Vice President of Human Resources	3yrs	no data	no data

3.0yrs

Average Tenure

46yo

Average Age

Experienced Management: EVL's management team is considered experienced (3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Moatazedi	President	6.5yrs	US$11.24m	no data
David Gill	Independent Director	6.8yrs	US$256.03k	0.043% € 332.4k
Simone Blank	Director	6.8yrs	US$235.03k	0.86% € 6.6m
Albert White	Independent Director	less than a year	no data	no data
Vikram Malik	Chairman of the Board	6.8yrs	US$271.03k	0.37% € 2.8m
Karah Parschauer	Independent Director	5.3yrs	US$249.03k	0.049% € 377.6k
Brady Stewart	Independent Director	2.8yrs	US$222.03k	0.071% € 541.5k

6.5yrs

Average Tenure

54yo

Average Age

Experienced Board: EVL's board of directors are considered experienced (6.5 years average tenure).

Evolus Management

Management criteria checks 2/4

Key information

Recent management updates

Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee

President recently sold €1.6m worth of stock

President recently sold €190k worth of stock

Evolus, Inc. Announces Board Changes

President recently sold €1.2m worth of stock

Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications

Recent updates

Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.30 loss in 3Q 2023)

Evolus, Inc. Provides Earnings Guidance for the Year 2024

Evolus, Inc. Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Evolus, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.32 loss in 2Q 2023)

Evolus, Inc. Raises Financial Guidance for the Full Year of 2024

Evolus, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

President recently sold €1.6m worth of stock

Evolus, Inc. Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

President recently sold €190k worth of stock

Forecast breakeven date moved forward to 2025

Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 1Q 2023)

Evolus, Inc. to Report Q1, 2024 Results on May 07, 2024

Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau

Evolus, Inc. Announces Board Changes

President recently sold €1.2m worth of stock

Evolus, Inc. has completed a Follow-on Equity Offering in the amount of $50.00478 million.

Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024

Full year 2023 earnings released: US$1.08 loss per share (vs US$1.33 loss in FY 2022)

Evolus, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Evolus, Inc. Announces Earnings Guidance for 2024

Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications

New minor risk - Shareholder dilution

President recently sold €765k worth of stock

New minor risk - Insider selling

No longer forecast to breakeven

Evolus, Inc. Raises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.30 loss per share (vs US$0.36 loss in 3Q 2022)

Evolus, Inc. Announces Results from the Phase 2 Clinical Study Evaluating the "Extra- strength" 40U Dose for Extended Duration of Jeuveau

Evolus, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Evolus, Inc. Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

President recently sold €139k worth of stock

Evolus, Inc. Unveils New Branding for Product Jeuveau to Reflect Growing and Evolving Consumers

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.42 loss in 2Q 2022)

New major risk - Share price stability

Evolus, Inc. Revises Revenue Guidance for the Year 2023

Evolus Launches Nuceiva (Botulinum Toxin Type A) in Italy

Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau (R)

First quarter 2023 earnings released: US$0.26 loss per share (vs US$0.31 loss in 1Q 2022)

Evolus, Inc. Provides Revenue Guidance for the Year 2023

Evolus, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: US$1.33 loss per share (vs US$0.94 loss in FY 2021)

Evolus, Inc. Announces "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase Ii Data Results, Representing Prolonged 6-Month Performance

Evolus, Inc. Receives Regulatory Approval for Nuceiva® in Australia

Evolus, Inc. Provides Earnings Guidance for the Year 2023

Forecast to breakeven in 2025

Insufficient new directors

Third quarter 2022 earnings released: US$0.36 loss per share (vs US$0.35 loss in 3Q 2021)

Evolus, Inc. Provides Earnings Guidance for the Full Year 2022

Evolus, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Independent Director recently bought €92k worth of stock

Evolus, Inc. Names Sandra Beaver as Its Chief Financial Officer, Effective September 5, 2022

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.30 loss in 2Q 2021)

Evolus, Inc. Reaffirms Revenue Guidance for Full Year 2022

Insufficient new directors

Evolus, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Evolus, Inc. Completes Patient Enrollment in Phase II Clinical Study Evaluating Extra-Strength Dose of Jeuveau

Evolus, Inc. Announces Dermatologic Surgery Published A New Post Hoc Analysis of Its Phase III Studies Comparing Millennial Patients to Non-Millennials

Independent Director recently sold €132k worth of stock

Evolus, Inc. Revises Earnings Guidance for the Year 2022

First quarter 2022 earnings released: US$0.31 loss per share (vs US$0.17 profit in 1Q 2021)

Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau

Evolus, Inc. Reaffirms Revenue Guidance for the Full-Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations